• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Reply to Letter to the Editor by Dr. Terry J. Smith regarding teprotumumab and ototoxicity.

作者信息

Bartalena L, Marcocci C, Tanda M L, Marinò M

机构信息

Department of Medicine and Surgery, University of Insubria, Via Ravasi, 2, 21100, Varese, Italy.

Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.

出版信息

J Endocrinol Invest. 2022 Aug;45(8):1603-1604. doi: 10.1007/s40618-022-01829-z. Epub 2022 May 28.

DOI:10.1007/s40618-022-01829-z
PMID:35633498
Abstract
摘要

相似文献

1
Reply to Letter to the Editor by Dr. Terry J. Smith regarding teprotumumab and ototoxicity.对特里·J·史密斯博士关于替普罗珠单抗与耳毒性的致编辑信的回复
J Endocrinol Invest. 2022 Aug;45(8):1603-1604. doi: 10.1007/s40618-022-01829-z. Epub 2022 May 28.
2
Teprotumumab for Graves' orbitopathy and ototoxicity: moving problems from eyes to ears?替普罗单抗治疗格雷夫斯眼病与耳毒性：问题从眼睛转移到耳朵了吗？
J Endocrinol Invest. 2022 Jul;45(7):1455-1457. doi: 10.1007/s40618-022-01791-w. Epub 2022 Apr 11.
3
Ototoxicity and Teprotumumab.耳毒性和特罗曲珠单抗。
Ann Otol Rhinol Laryngol. 2022 Aug;131(8):910-913. doi: 10.1177/00034894211042740. Epub 2021 Aug 27.
4
Teprotumumab: First Approval.特罗替珠单抗：首次获批
Drugs. 2020 Apr;80(5):509-512. doi: 10.1007/s40265-020-01287-y.
5
Teprotumumab: Interpreting the Clinical Trials in the Context of Thyroid Eye Disease Pathogenesis and Current Therapies.特罗特单抗：从甲状腺眼病发病机制和现有疗法的角度解读临床试验。
Ophthalmology. 2021 Nov;128(11):1627-1651. doi: 10.1016/j.ophtha.2021.04.024. Epub 2021 Apr 28.
6
Thyroid Eye Disease, Teprotumumab, and Hearing Loss: An Evolving Role for Otolaryngologists.甲状腺眼病、替普罗单抗与听力损失：耳鼻喉科医生的角色演变
Otolaryngol Head Neck Surg. 2021 Dec;165(6):757-758. doi: 10.1177/01945998211004240. Epub 2021 Mar 30.
7
Teprotumumab: a new avenue for the management of moderate-to-severe and active Graves' orbitopathy?替普罗单抗：治疗中重度活动性格雷夫斯眼眶病的新途径？
J Endocrinol Invest. 2017 Aug;40(8):885-887. doi: 10.1007/s40618-017-0717-8. Epub 2017 Jun 20.
8
Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trials.替普罗单抗治疗活动性甲状腺眼病患者：两项随机、双盲、安慰剂对照、多中心试验的汇总数据分析、亚组分析及停药后随访结果
Lancet Diabetes Endocrinol. 2021 Jun;9(6):360-372. doi: 10.1016/S2213-8587(21)00056-5. Epub 2021 Apr 15.
9
Bilateral dysthyroid compressive optic neuropathy responsive to teprotumumab.对替普罗单抗有反应的双侧甲状腺功能障碍性压迫性视神经病变
Eur J Ophthalmol. 2022 May;32(3):NP46-NP49. doi: 10.1177/1120672121991042. Epub 2021 Feb 1.
10
Teprotumumab Efficacy, Safety, and Durability in Longer-Duration Thyroid Eye Disease and Re-treatment: OPTIC-X Study.替普罗珠单抗在长期甲状腺眼病及再治疗中的疗效、安全性和持久性：OPTIC-X研究
Ophthalmology. 2022 Apr;129(4):438-449. doi: 10.1016/j.ophtha.2021.10.017. Epub 2021 Oct 21.

引用本文的文献

1
Letter to the editor regarding Bartalena et al. 2022.致编辑的信：关于巴尔塔莱纳等人（2022年）的研究
J Endocrinol Invest. 2022 Aug;45(8):1601-1602. doi: 10.1007/s40618-022-01828-0. Epub 2022 Jun 1.

本文引用的文献

1
Letter to the editor regarding Bartalena et al. 2022.致编辑的信：关于巴尔塔莱纳等人（2022年）的研究
J Endocrinol Invest. 2022 Aug;45(8):1601-1602. doi: 10.1007/s40618-022-01828-0. Epub 2022 Jun 1.
2
Proptosis and Diplopia Response With Teprotumumab and Placebo vs the Recommended Treatment Regimen With Intravenous Methylprednisolone in Moderate to Severe Thyroid Eye Disease: A Meta-analysis and Matching-Adjusted Indirect Comparison.特罗特单抗和安慰剂与静脉注射甲基强的松龙推荐治疗方案治疗中重度甲状腺眼病的突眼和复视反应：一项荟萃分析和匹配调整间接比较。
JAMA Ophthalmol. 2022 Apr 1;140(4):328-335. doi: 10.1001/jamaophthalmol.2021.6284.
3
Teprotumumab Efficacy, Safety, and Durability in Longer-Duration Thyroid Eye Disease and Re-treatment: OPTIC-X Study.
替普罗珠单抗在长期甲状腺眼病及再治疗中的疗效、安全性和持久性：OPTIC-X研究
Ophthalmology. 2022 Apr;129(4):438-449. doi: 10.1016/j.ophtha.2021.10.017. Epub 2021 Oct 21.
4
Teprotumumab for the Treatment of Active Thyroid Eye Disease.特罗特鲁单抗治疗活动性甲状腺眼病。
N Engl J Med. 2020 Jan 23;382(4):341-352. doi: 10.1056/NEJMoa1910434.